Cargando…

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity

Adoptive T-cell therapy with T cell receptor (TCR) -engineered T cells is an attractive strategy for cancer treatment and the success in this therapy is dependent on the functional avidity of the transduced TCRs against targeted tumor antigens. Therefore, the establishment of the methodology of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morimoto, Soyoko, Fujiki, Fumihiro, Kondo, Kenta, Nakajima, Hiroko, Kobayashi, Yoshiki, Inatome, Miki, Aoyama, Nao, Nishida, Yuya, Tsuboi, Akihiro, Oka, Yoshihiro, Nishida, Sumiyuki, Nakata, Jun, Hosen, Naoki, Oji, Yusuke, Sugiyama, Haruo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6183340/ https://www.ncbi.nlm.nih.gov/pubmed/30344927 http://dx.doi.org/10.18632/oncotarget.26139

Ejemplares similares

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs
por: Fujiki, Fumihiro, et al.
Publicado: (2023)

A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
por: Tsuboi, Akihiro, et al.
Publicado: (2018)

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
por: Takashima, Satoshi, et al.
Publicado: (2016)

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells
por: Hasegawa, Kana, et al.
Publicado: (2015)

Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments
por: Nishida, Sumiyuki, et al.
Publicado: (2019)

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine
por: Alzaaqi, Shouq, et al.
Publicado: (2022)

T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy
por: Fujiki, Fumihiro, et al.
Publicado: (2022)

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms
por: Tatsumi, Naoya, et al.
Publicado: (2015)

WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers
por: Oka, Yoshihiro, et al.
Publicado: (2007)

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2022)

Imaging Assessment of Tumor Response in the Era of Immunotherapy
por: Nakata, Jun, et al.
Publicado: (2021)

Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT
por: Nakata, Jun, et al.
Publicado: (2020)

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis
por: Hasegawa, Kana, et al.
Publicado: (2016)

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides
por: Nakata, Jun, et al.
Publicado: (2018)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
por: Minagawa, Hikaru, et al.
Publicado: (2023)

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
por: Nakagawa, Natsuki, et al.
Publicado: (2022)

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023)

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2014)

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine
por: Maeda, T, et al.
Publicado: (2013)

The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
por: OJI, YUSUKE, et al.
Publicado: (2014)

Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies
por: Yokota, Chisato, et al.
Publicado: (2021)

IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS’ TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS
por: Kagawa, Naoki, et al.
Publicado: (2019)

Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review
por: Hashii, Yoshiko, et al.
Publicado: (2020)

Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth
por: Oji, Yusuke, et al.
Publicado: (1999)

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
por: Versteven, Maarten, et al.
Publicado: (2018)

P1369: HDAC INHIBITION INVOLVES CD26 EXPRESSION ON MULTIPLE MYELOMA CELLS VIA THE C-MYC/SP1-MEDIATED PROMOTER ACTIVATION AND OVERCOMES THERAPEUTIC RESISTANCE BY HUMANIZED ANTIBODY
por: Nishida, Hiroko, et al.
Publicado: (2023)

Avid Editing
por: Kauffmann, Sam, et al.
Publicado: (2017)

An Avid Imitator
por: Farmakiotis, Dimitrios, et al.
Publicado: (2016)

Editing with Avid Media Composer 5: the official Avid guide.
por: Kennedy, Ashley
Publicado: (2010)

Genome-wide copy number variation analysis of hepatitis B infection in a Japanese population
por: Kikuchi, Masataka, et al.
Publicado: (2021)

Proposal of a Comprehensive and Multi-Component Approach to Promote Physical Activity among Japanese Office Workers: A Qualitative Focus Group Interview Study
por: Kim, Jihoon, et al.
Publicado: (2022)

Multi-Component Intervention to Promote Physical Activity in Japanese Office Workers: A Single-Arm Feasibility Study
por: Kim, Jihoon, et al.
Publicado: (2022)

The Avid handbook: advanced techniques, strategies, and survival information for Avid editing systems
por: Staten, Greg, et al.
Publicado: (2009)

Repeated rough coiling technique of portosystemic shunt: A novel treatment for hepatic encephalopathy
por: Nakano, Mariko, et al.
Publicado: (2023)

Low Avidity T Cells Do Not Hinder High Avidity T Cell Responses Against Melanoma
por: Ioannidou, Kalliopi, et al.
Publicado: (2019)

Orchestration of Intracellular Circuits by G Protein-Coupled Receptor 39 for Hepatitis B Virus Proliferation
por: Goto, Kaku, et al.
Publicado: (2020)

CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
por: Nishida, Hiroko, et al.
Publicado: (2018)

Avid Liquid 7 for Windows
por: Ekert, Paul
Publicado: (2005)

A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition
por: Hayashi, Mutsumi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qrouk2treki2810atlunjm3r8l